Health Care & Life Sciences » Biotechnology | Esperion Therapeutics Inc.

Esperion Therapeutics Inc. | Mutual Funds

Mutual Funds that own Esperion Therapeutics Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
BB Biotech AG
2,412,964
9%
315,000
2.87%
03/31/2018
SPDR S&P Biotech ETF
1,881,066
7.02%
4,839
1.59%
09/06/2018
Fidelity Select Biotechnology Portfolio
677,084
2.52%
-42,300
0.37%
07/31/2018
Vanguard Total Stock Market Index Fund
599,518
2.24%
0
0%
07/31/2018
HBM BioVentures Ltd.
580,748
2.17%
748
1.95%
12/31/2017
iShares Russell 2000 ETF
478,988
1.79%
-255
0.05%
09/06/2018
Rhenman & Partners Fund - Healthcare Equity L/S
386,626
1.44%
23,279
1.36%
12/31/2017
iShares Nasdaq Biotechnology ETF
309,057
1.14%
-4,032
0.16%
09/06/2018
Vanguard Small Cap Index Fund
302,580
1.12%
3,977
0.02%
07/31/2018
Wasatch Small Cap Growth Fund
287,373
1.07%
-52,521
0.69%
03/31/2018

About Esperion Therapeutics

View Profile
Address
3891 Ranchero Drive
Ann Arbor Michigan 48108
United States
Employees -
Website http://www.esperion.com
Updated 07/08/2019
Esperion Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). It offers Bempedoic acid and Ezetime combination pill as therapies that have been shown to lower elevated LDL-C levels in patients with hypercholesterolemia, including patients inadequately treated with current lipid-modifying therapies. The company was founded by Roger S.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.